DSC1: A Drug Target / Disease Biomarker (G1823)

Target Name: DSC1

NCBI ID: G1823

DSC1

DSC1: A Drug Target / Disease Biomarker

DSC1 (Dipeptidyl-L-Leucine) is a drug target and a biomarker that has been shown to have a role in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and chemical properties make it an attractive target for drug development.

DSC1 is a small protein that is expressed in various tissues and cells in the body. It is composed of two distinct regions: an N-terminal region that contains a unique amino acid sequence, and a C-terminal region that contains a glycine-rich loop and a leucine side chain. The N-terminal region is known as the leucine-rich region or LRR, and it is the region that gives DSC1 its unique structure and its ability to interact with other proteins.

The LRR is a key region that contains several unique amino acids that are not found in other proteins. The most prominent of these amino acids is alanine, which is a polar amino acid that has a negatively charged side and a positively charged back. This structure gives DSC1 its electrostatic potential, which is important for its ability to interact with other proteins.

DSC1 has been shown to play a role in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, DSC1 has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Studies have shown that DSC1 levels are decreased in the brains of individuals with these conditions, and that levels are increased in the brains of individuals who have the genes for these conditions.

DSC1 has also been shown to be involved in the development of cancer. Studies have shown that DSC1 is expressed in various types of cancer, and that it is involved in the development of cancer by promoting the growth and survival of cancer cells.

DSC1 has also been shown to be involved in autoimmune disorders. Studies have shown that DSC1 is involved in the development of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.

In conclusion, DSC1 is a drug target and biomarker that has been shown to play a role in various diseases. Its unique structure and chemical properties make it an attractive target for drug development. Further research is needed to fully understand the role of DSC1 in these diseases and to develop effective treatments.

Protein Name: Desmocollin 1

Functions: Component of intercellular desmosome junctions. Involved in the interaction of plaque proteins and intermediate filaments mediating cell-cell adhesion. May contribute to epidermal cell positioning (stratification) by mediating differential adhesiveness between cells that express different isoforms. Linked to the keratinization of epithelial tissues

The "DSC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DSC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets